SS-31 Peptide Combinations: What the Research Says About Stacking

What Is SS-31?

SS-31 peptide is a mitochondria-targeting tetrapeptide, also known by its clinical alias elamipretide and by the research name Bendavia. It selectively concentrates at the inner mitochondrial membrane, where it associates with cardiolipin — a phospholipid essential for the structural integrity of the electron transport chain. Developed to address mitochondrial dysfunction at its source, SS-31 has been studied across cardiovascular, renal, musculoskeletal, and hepatic disease models. Because mitochondrial failure underlies so many age-related and injury-driven pathologies, researchers have begun testing it not in isolation but alongside other mitochondrial-support compounds, examining whether combination approaches produce effects that neither agent achieves alone.

---

What Is SS-31 Studied For?

Research on SS-31 goes back to 2019 — 7 years — with studies continuing through 2026.

1. Age-Related Cardiac Dysfunction — A 2021 preclinical study in old male mice reported that SS-31 partially reversed an age-related decline in diastolic heart function, an effect that was distinct from, and complementary to, the systolic improvements produced by NMN.

2. Cisplatin-Induced Acute Kidney Injury — A preclinical study in male C57BL/6 mice (n=32) found that SS-31 attenuated cisplatin-driven kidney injury by modulating the mitochondrial ROS–NLRP3 inflammasome pathway in both in vivo and in vitro models.

3. Metabolic Liver Disease — A 2026 preclinical study in aged female mice under nutritional stress reported that SS-31 improved mitochondrial function and reduced markers of oxidative stress in a metabolic dysfunction-associated steatotic liver disease model.

4. Skeletal Muscle Performance in Heart Failure — A 2026 preclinical study in a rat heart failure with preserved ejection fraction model (n=10) found that SS-31 improved skeletal muscle contractile performance, an outcome linked to its cardiolipin-stabilizing activity.

5. Sensory Hair Cell Protection — A 2019 preclinical study in zebrafish reported dose-dependent protection of lateral line hair cells against gentamicin-induced toxicity following Bendavia pretreatment.

---

How Does SS-31 Work?

SS-31 carries a net positive charge that drives its accumulation at the inner mitochondrial membrane, where it binds cardiolipin. Cardiolipin organizes the respiratory chain supercomplexes that carry out electron transfer; when its structure is disrupted — by oxidative stress, aging, or metabolic disease — electron leakage increases, producing excess reactive oxygen species (ROS) and reducing ATP output. By stabilizing cardiolipin, SS-31 preserves supercomplex architecture, limits ROS generation at the source, and supports efficient ATP synthesis.

That mechanism is different in kind from NAD⁺ precursor supplementation, which works by replenishing a cofactor consumed across hundreds of metabolic reactions. The difference matters for combination research: two compounds acting on distinct nodes of the same pathway can produce additive or even synergistic effects, but they can also interfere. The studies below test exactly that premise.

---

What Animal Research Shows About SS-31 Combinations

SS-31 Combined With NMN in Aged Mouse Hearts

The most systematically designed combination study in the pool is a 2021 preclinical study in old male mice that compared SS-31 alone, NMN alone, and the two compounds together on cardiac function. Assessed by echocardiography, SS-31 partially reversed the age-related decline in diastolic function, while NMN fully reversed an age-related deficiency in systolic function at higher cardiac workloads. The combination did not produce uniform additive benefit — metabolomic analysis revealed distinct and in some cases non-overlapping metabolite signatures for each treatment arm. The finding argues that the two compounds address different functional deficits rather than redundantly targeting the same one.

SS-31 Combined With NMN in Aged Kidneys

A 2024 preprint preclinical study in young (6-month) and aged (26-month) adult male mice extended the cardiac comparison to renal tissue. The study tested both compounds against the backdrop of age-specific kidney inflammation and declining NAD⁺ levels in mitochondria-rich tubule cells. Notably, NMN supplementation alone drove accumulation of certain metabolic byproducts in aged kidney tissue — an effect not observed in young animals — complicating the assumption that NAD⁺ repletion is uniformly beneficial across tissues. SS-31 was tested as an alternative mitochondrial intervention in this setting. The study highlights that combination or sequential use of mitochondrial agents may produce tissue-specific outcomes that single-organ studies would not predict.

SS-31 Versus MitoQ in a Liver Disease Model

A 2026 preclinical study in aged female mice under nutritional stress compared SS-31 and MitoQ — two structurally unrelated mitochondria-targeted antioxidants — for their effects on mitochondrial function, oxidative stress, and liver inflammation in a metabolic dysfunction-associated steatotic liver disease model. Rather than combining the agents, this study used a head-to-head comparative design, which provides useful context for stacking questions: if two compounds target overlapping mechanisms (both reduce mitochondrial ROS), the incremental value of combining them is less obvious than if their mechanisms are orthogonal. The study's comparative framing is itself informative — researchers chose this design precisely because the mechanistic overlap between SS-31 and MitoQ raised the question of whether one could substitute for the other.

SS-31 and Mitophagy Pathway Modulation in Tendon Heterotopic Ossification

A 2026 preclinical study examined SS-31 in a model of trauma-induced tendon heterotopic ossification — pathological bone formation in tendon tissue. The study's focus was ANT1, a mitochondrial transport protein whose inhibition activates PINK1/Parkin-mediated mitophagy (selective clearance of damaged mitochondria). SS-31 was evaluated in combination with ANT1-targeting interventions, with results indicating that coordinating mitophagy induction with mitochondrial membrane stabilization reduced osteogenic differentiation of tendon progenitor cells. This is a distinct combination logic: rather than pairing two antioxidants, the approach pairs a membrane-stabilizing agent (SS-31) with a pathway that removes irreparably damaged mitochondria — a potentially complementary sequence.

SS-31 in a Heart Failure–Skeletal Muscle Model

A 2026 preclinical study in a rat heart failure with preserved ejection fraction model (n=10) used SS-31 as a single agent targeting cardiolipin integrity in skeletal muscle. The study confirmed that mitochondrial dysfunction in skeletal muscle — not just cardiac muscle — contributes to exercise intolerance in this condition. While this study did not test a combination, it establishes skeletal muscle as a tissue of interest for SS-31 and frames the question of whether pairing it with exercise-capacity interventions would compound benefit.

SS-31 and Neuroprotection Against Methanol Toxicity

A 2025 preclinical study in male Wistar Albino rats (n=40) evaluated SS-31 (elamipretide) alongside methylprednisolone — a corticosteroid — for biochemical and histopathological protection against methanol poisoning-induced damage to optic nerve, retina, and brain tissue. The combination context here is a pharmacological one: SS-31 was assessed in a model where standard-of-care treatment (methylprednisolone) was already present. The study's histopathological evaluation across three neural tissue types provides one of the broader anatomical scopes in this pool, though the authors' specific findings regarding the interaction between the two agents require reading the full study text.

---

What Human Research Shows

No human clinical trial data within the provided study pool directly addresses SS-31 combination protocols. The human trial literature on elamipretide — including work in Barth syndrome, heart failure with reduced ejection fraction, and primary mitochondrial myopathy — exists but was not retrieved in the current pool and therefore cannot be cited here. The combination findings described above are limited to animal and in vitro models. Extrapolating combination outcomes from rodent or zebrafish data to human contexts is not supported by the current evidence base.

---

What's Still Unknown

The central gap is straightforward: no study in this pool tests an SS-31 combination in human subjects. The animal data suggests that pairing SS-31 with NMN produces cardiac outcomes that differ functionally by chamber and by age group — a finding that complicates simple "more is better" reasoning — but whether this interaction holds in human cardiac tissue is unresolved. The 2024 kidney preprint raises a separate concern: NAD⁺ precursor supplementation in aged animals produced metabolite accumulation patterns not seen in young animals, which means the safety profile of SS-31 plus NMN combinations may differ by age cohort even in rodent models. The head-to-head MitoQ comparison in liver disease suggests mechanistic overlap between mitochondria-targeted antioxidants, making the additive value of stacking two such compounds uncertain without direct combination data. Research needed to answer the stacking question rigorously would require factorial-design trials with tissue-specific outcome measures, adequate aging-cohort stratification, and — ultimately — human trial replication.

---

Where Can I Buy SS-31?

SS-31 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---